Caris Life Sciences, a leading player in the precision medicine industry, is headquartered in France and operates extensively across Europe and North America. Founded in 2008, the company has made significant strides in advancing cancer care through its innovative molecular profiling services. Caris Life Sciences offers a unique suite of products, including comprehensive genomic profiling and biomarker testing, which empower healthcare providers to tailor treatments to individual patients. Their commitment to precision medicine has positioned them as a trusted partner in oncology, with notable achievements in improving patient outcomes. With a focus on integrating advanced technologies and data analytics, Caris Life Sciences continues to set benchmarks in the industry, driving forward the future of personalised medicine.
How does Caris Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Caris Life Sciences's score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Caris Life Sciences reported a Scope 3 emissions intensity of approximately 0.00037 kg CO2e per € gross profit, a reduction from about 0.00049 kg CO2e per € gross profit in 2022. This indicates a positive trend in their emissions management efforts, focusing on minimising their carbon footprint associated with upstream activities. While specific absolute emissions data for Scope 1 and Scope 2 are not disclosed, the company has not outlined any formal reduction targets or climate pledges. This suggests that while they are making strides in reducing emissions intensity, there may be opportunities for more comprehensive climate commitments and transparency regarding their overall emissions profile. Caris Life Sciences is positioned within an industry increasingly focused on sustainability, and their ongoing efforts to reduce emissions intensity reflect a growing awareness of climate impact. As they continue to evolve their strategies, further commitments could enhance their environmental stewardship and align with broader industry standards.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Caris Life Sciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.